Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NCZ Stock Summary
Top 10 Correlated ETFs
NCZ
In the News

CEF Weekly Review: More Of The Same On The Distribution Front
We review CEF market valuation and performance through the second week of March and highlight recent market action. CEFs mostly struggled, outside of the higher-quality sectors as two bank failures spooked markets.

NCV And NCZ: Discounts Narrow For Both, But One Looking More Appealing
NCV and NCZ have seen their discounts narrow from the wide discount we saw several months ago. NCZ presents a potentially better opportunity with a larger discount compared to NCV.

NCZ.PA: This 6.3% A-Rated Preferred Stock Suffers From Market Discrimination
Leverage restrictions make any CEF preferred stock relatively safe from a credit perspective. Comparison to bank preferreds through the years.

Weekly Closed-End Fund Roundup: Tortoise Tender Results, NCZ Resumes Distributions (November 6, 2022)
12 out of 23 CEF sectors positive on price and 6 out of 23 sectors positive on NAV last week. Tortoise offer tender results.

NCZ: Distribution Suspension And Resumption Creates Swap Opportunity With NCV
NCZ has suspended, and resumed, distributions. Both NCV and NCZ have deleveraged by redeeming their ARPS.

Weekly Closed-End Fund Roundup: Tortoise Tender Offers Expiring (October 23, 2022)
16 out of 23 CEF sectors positive on price and 12 out of 23 sectors positive on NAV last week. Watch for overvalued CEFs as market volatility rises.

Weekly Closed-End Fund Roundup: BlackRock CEFs Repurchasing Shares (October 16, 2022)
0 out of 23 CEF sectors are positive on price and 0 out of 23 sectors are positive on NAV over the last week. BlackRock CEFs are repurchasing their shares.

CEF Weekly Review: Be Careful When Evaluating Long-Term Performance
We review CEF market valuation and performance through the first week of October and highlight recent market action. The CEF space was up on the week, led by higher-beta sectors.

NCZ Postpones Its Distribution (Again)
NCZ postpones its distribution (again). This was due to it falling below minimum asset coverage requirements.

NCZ: Q&A About The Fund's Distribution Suspension
NCZ recently suspended its distribution, though it ended up paying it shortly after. We discuss some of the reasons behind this unusual, though not very surprising, event.
NCZ Financial details
NCZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-02-28
Metric | History | 2017-02-28 | 2018-02-28 | 2019-02-28 | 2020-02-29 | 2021-02-28 |
---|---|---|---|---|---|---|
Revenue per share | 0.74 | 0.56 | -0.06 | 0.47 | 1.64 | |
Net income per share | 1.96 | 0.55 | -0.08 | 0.46 | 1.63 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0.01 | 0 | 0 | |
Book value per share | 9.82 | 6.67 | 8.62 | 8.35 | 9.85 | |
Tangible book value per share | 9.82 | 6.67 | 8.62 | 8.35 | 9.85 | |
Share holders equity per share | 9.82 | 6.67 | 8.62 | 8.35 | 9.85 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 459.23M | 402.76M | 411.17M | 345.57M | 374.1M | |
Enterprise value | 459.23M | 402.76M | 410.13M | 345.57M | 374.1M | |
P/E ratio | 3.15 | 11.09 | -71.97 | 9.97 | 3.17 | |
Price to sales ratio | 8.37 | 10.85 | -89.81 | 9.74 | 3.15 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0.63 | 0.92 | 0.63 | 0.54 | 0.53 | |
PTB ratio | 0.63 | 0.92 | 0.63 | 0.54 | 0.53 | |
EV to sales | 8.37 | 10.85 | -89.58 | 9.74 | 3.15 | |
Enterprise value over EBITDA | 3.15 | 11.09 | -76.37 | 9.97 | 3.17 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0.32 | 0.09 | -0.01 | 0.1 | 0.32 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.01 | 0.64 | 0.04 | 0.01 | 0.03 | |
Debt to assets | 0.01 | 0.39 | 0.04 | 0.01 | 0.03 | |
Net debt to EBITDA | 0 | 0 | 0.19 | 0 | 0 | |
Current ratio | 2.2 | 0 | 0 | 0 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.02 | -0.24 | 0.02 | 0.01 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 20.81 | 9.08 | 3.83 | 9.25 | 19 | |
ROIC | 0.2 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0.2 | 0.05 | -0.01 | 0.05 | 0.16 | |
Graham Net | 0.04 | -4.09 | -0.13 | 0 | -0.2 | |
Working capital | 5.9M | 0 | 0 | 0 | 0 | |
Tangible asset value | 731M | 440.11M | 651.43M | 635.91M | 712.52M | |
Net current asset value | 5.9M | -280.83M | -25.05M | -6.06M | -18.68M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 10.8M | 12.3M | 16.23M | 13.13M | 6.8M | |
Average payables | 0 | 3.23M | 15.59M | 15.28M | 12.07M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 70.49 | 137.53 | -1.47K | 80.16 | 17.86 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 5.18 | 2.65 | -0.25 | 4.55 | 20.44 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.2 | 0.08 | -0.01 | 0.05 | 0.17 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-08-31 for Q2
Metric | History | 2019-08-31 | 2020-02-29 | 2020-08-31 | 2021-02-28 | 2021-08-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.28 | 0 | 0 | 0 | 0 | |
Net income per share | 0.36 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 7.17 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 7.17 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 7.17 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 378.13M | 0 | 0 | 0 | 0 | |
Enterprise value | 378.13M | -438 | -533 | -3.66K | -503K | |
P/E ratio | 3.43 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 17.5 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0.69 | 0 | 0 | 0 | 0 | |
PTB ratio | 0.69 | 0 | 0 | 0 | 0 | |
EV to sales | 17.5 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 13.7 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0.07 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.21 | 0.01 | 0.01 | 0.03 | 0.01 | |
Debt to assets | 0.17 | 0.01 | 0.01 | 0.03 | 0.01 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 0 | 0 | 0 | 0 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 7.66 | 0 | 0 | 0 | 0 | |
ROIC | 0.04 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0.04 | 0 | 0 | 0 | 0 | |
Graham Net | -1.44 | 0 | 0 | 0 | 0 | |
Working capital | 0 | 0 | 0 | 0 | 0 | |
Tangible asset value | 544.29M | 635.91M | 642M | 712.52M | 707.72M | |
Net current asset value | -115.37M | -6.06M | -4.43M | -18.68M | -6.8M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 13.05M | 7.72M | 7.39M | 6.4M | 5.73M | |
Average payables | 15.42M | 5.98M | 5.02M | 11.24M | 12.15M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 31.85 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 210.98 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.83 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.43 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.05 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NCZ Frequently Asked Questions
What is Virtus AllianzGI Convertible & Income Fund II stock symbol ?
Virtus AllianzGI Convertible & Income Fund II is a US stock , located in New york of Ny and trading under the symbol NCZ
What is Virtus AllianzGI Convertible & Income Fund II stock quote today ?
Virtus AllianzGI Convertible & Income Fund II stock price is $2.87 today.
Is Virtus AllianzGI Convertible & Income Fund II stock public?
Yes, Virtus AllianzGI Convertible & Income Fund II is a publicly traded company.